Liquidia (LQDA) Cash & Equivalents (2020 - 2026)
Liquidia (LQDA) posted quarterly Cash & Equivalents of $222.8 million for Q1 2026, up 31.24% year-over-year from $169.8 million in Q1 2025, and up 16.84% quarter-over-quarter from $190.7 million in Q4 2025.
Liquidia (LQDA) Cash & Equivalents (2020 - 2026) Analysis & Trends
Liquidia's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $222.8 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 31.24% year-over-year to $222.8 million; the TTM figure through Mar 2026 stood at $222.8 million (up 31.24% YoY), while the FY2025 annual figure was $190.7 million, up 8.05% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $222.8 million, up from $190.7 million in the prior quarter.
- The five-year high for Cash & Equivalents was $222.8 million in Q1 2026, with the low at $57.8 million in Q1 2022.
- The 5-year median for Cash & Equivalents is $133.1 million (2024), against an average of $134.2 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 168.11% in 2024, then retreated 22.94% in 2025.
- Liquidia's Cash & Equivalents stood at $93.3 million in 2022, then slipped by 10.3% to $83.7 million in 2023, then surged by 110.9% to $176.5 million in 2024, then gained by 8.05% to $190.7 million in 2025, then rose by 16.84% to $222.8 million in 2026.
- Business Quant data shows LQDA's Cash & Equivalents at $222.8 million in Q1 2026, $190.7 million in Q4 2025, and $157.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Liquidia | 6.39 Bn | 6.10 Bn | 160.92 Mn | 284.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284.18 Mn |
| Mar 31, 2026 | 222.79 Mn |
| Dec 31, 2025 | 190.68 Mn |
| Sep 30, 2025 | 157.50 Mn |
| Jun 30, 2025 | 173.42 Mn |
| Mar 31, 2025 | 169.76 Mn |
| Dec 31, 2024 | 176.48 Mn |
| Sep 30, 2024 | 204.37 Mn |
| Jun 30, 2024 | 133.09 Mn |
| Mar 31, 2024 | 157.86 Mn |
| Dec 31, 2023 | 83.68 Mn |
| Sep 30, 2023 | 76.23 Mn |
| Jun 30, 2023 | 88.20 Mn |
| Mar 31, 2023 | 94.41 Mn |
| Dec 31, 2022 | 93.28 Mn |
| Sep 30, 2022 | 98.32 Mn |
| Jun 30, 2022 | 103.84 Mn |
| Mar 31, 2022 | 57.80 Mn |
| Dec 31, 2021 | 57.49 Mn |
| Sep 30, 2021 | 64.10 Mn |